BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities.
Hu CB, Chen CP, Yeh TK, Song JS, Chang CY, Chuu JJ, Tung FF, Ho PY, Chen TW, Lin CH, Wang MH, Chang KY, Huang CL, Lin HL, Li WT, Hwang DR, Chern JH, Hwang LL, Chang JY, Chao YS, Chen CT.
Hu CB, et al. Among authors: lin ch, lin hl.
Cancer Sci. 2011 Jan;102(1):182-91. doi: 10.1111/j.1349-7006.2010.01744.x. Epub 2010 Oct 12.
Cancer Sci. 2011.
PMID: 21040217
Free article.